HOME
市場調査レポート
リキッドバイオプシー(液体生検）の世界市場：バイオマーカー別、臨床用途別2022年予測
Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022
- 出版元：MarketsandMarkets
出版元について - 発行年：2017年9月
- 定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文 206ページになります。
- 商品コード：MAM787
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
リキッドバイオプシー（液体生検）の世界市場規模は2016年段階で5億8000万ドルと推計され、今後2022年には20億4700万ドル市場に成長すると予測されます。がん患者の増加、非侵襲的処置への選好度の高まり、リキッドバイオプシー研究開発への投資増、などは同市場の支持要因と言えるでしょう。
当レポートでは、2022年に至るリキッドバイオプシー市場の世界市場予測(市場規模US$)、製品サービス別市場（アッセイキット、器具、サービス）、循環バイオマーカー別市場(循環腫瘍細胞、循環腫瘍DNA、無細胞DNA、細胞外小胞、その他)、臨床用途別市場(早期がんスクリーニング、治療選択、治療モニタリング、再発モニタリング)、疾病別市場(がん各種、がん以外)、エンドユーザー別市場(リファレンスラボ、病院/検査機関、学術/研究センター、その他)、主要国地域別市場など、各種の市場データおよび分析を掲載しています。また市場考察、競合分析、主要メーカー企業 社動向などの情報も交えて、リキッドバイオプシー市場の現在と今後展望を予測検証していきます。
【レポート構成概要】
◆ リキッドバイオプシーの世界市場予測2015-2022年
・市場規模(US$)
◆ 製品サービス別、市場-2022年
・アッセイキット
・器具
・サービス
※(市場規模US$)
◆ 循環バイオマーカー別、市場-2022年
・循環腫瘍細胞(CTC)
・循環腫瘍DNA(CTDNA)
・無細胞DNA
・細胞外小胞
・その他
※(市場規模US$)
◆ 臨床用途別、市場-2022年
・早期がんスクリーニング
・治療選択
・治療モニタリング
・再発モニタリング
※(市場規模US$)
◆ 疾病別、市場-2022年
がん
・肺がん
・乳がん
・大腸がん
・前立腺がん
・肝臓がん
・その他
がん以外
※(市場規模US$)
◆ エンドユーザー別、市場-2022年
・リファレンスラボ
・病院、検査機関
・学術、研究センター
・その他
※(市場規模US$)
◆主要国地域別市場-2022年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
その他地域
※ 国、地域ごとに全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・競合状況
◆ リキッドバイオプシーの主要企業プロフィール動向
・BIOCEPT, INC.
・QIAGEN N.V.
・ROCHE DIAGNOSTICS
・BIO-RAD LABORATORIES, INC.
・MYRIAD GENETICS, INC
・MENARINI-SILICON BIOSYSTEMS
・TROVAGENE, INC.
・GUARDANT HEALTH, INC.
・MDXHEALTH SA
・GENOMIC HEALTH, INC.
・RAINDANCE TECHNOLOGIES, INC
・THERMO FISHER SCIENTIFIC INC.
・ILLUMINA, INC.
（全206頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
英文詳細目次(table of contents)
【原文詳細目次】
Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022
Table of Contents
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Secondary sources 20
2.1.2 PRIMARY DATA 21
2.1.2.1 Primary sources 21
2.1.2.2 Key industry insights 22
2.2 MARKET SIZE ESTIMATION 22
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 LIQUID BIOPSY: MARKET OVERVIEW 31
4.2 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION (2017) 32
4.3 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 33
4.4 LIQUID BIOPSY MARKET: GEOGRAPHIC MIX 34
4.5 LIQUID BIOPSY MARKET: ESTABLISHED VS. EMERGING MARKETS 34
5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Increasing prevalence of cancer 36
5.2.1.2 Increasing preference for noninvasive procedures 37
5.2.1.3 Initiatives undertaken by government and global health organizations 38
5.2.1.4 Technological advancement to augment market revenues 39
5.2.1.5 Rising emphasis on personalized medicine 40
5.2.1.6 Availability of funding for liquid biopsy R&D 40
5.2.2 RESTRAINTS 43
5.2.2.1 Low sensitivity and specificity 43
5.2.3 OPPORTUNITIES 43
5.2.3.1 Growing interest in liquid biopsy 43
5.2.4 CHALLENGES 44
5.2.4.1 Unclear regulatory and reimbursement scenario 44
6 LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE 46
6.1 INTRODUCTION 47
6.2 ASSAY KITS 48
6.3 INSTRUMENTS 49
6.4 SERVICES 51
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 52
7.1 INTRODUCTION 53
7.2 CIRCULATING TUMOR CELLS 54
7.3 CIRCULATING TUMOR DNA (CTDNA) 55
7.4 CELL-FREE DNA 57
7.5 EXTRACELLULAR VESICLES (EVS) 58
7.6 OTHER CIRCULATING BIOMARKERS 59
8 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 61
8.1 INTRODUCTION 62
8.2 EARLY CANCER SCREENING 62
8.3 THERAPY SELECTION 63
8.4 TREATMENT MONITORING 64
8.5 RECURRENCE MONITORING 65
9 LIQUID BIOPSY MARKET, BY APPLICATION 67
9.1 INTRODUCTION 68
9.2 CANCER APPLICATIONS 68
9.2.1 LUNG CANCER 70
9.2.2 BREAST CANCER 72
9.2.3 COLORECTAL CANCER 73
9.2.4 PROSTATE CANCER 75
9.2.5 LIVER CANCER 76
9.2.6 OTHER CANCERS 77
9.3 NON-CANCER APPLICATIONS 78
10 LIQUID BIOPSY MARKET, BY END USER 80
10.1 INTRODUCTION 81
10.2 REFERENCE LABORATORIES 81
10.3 HOSPITALS AND PHYSICIAN LABORATORIES 82
10.4 ACADEMIC AND RESEARCH CENTERS 83
10.5 OTHER END USERS 85
11 LIQUID BIOPSY MARKET, BY REGION 86
11.1 INTRODUCTION 87
11.2 NORTH AMERICA 88
11.2.1 US 93
11.2.2 CANADA 97
11.3 EUROPE 101
11.3.1 GERMANY 106
11.3.2 FRANCE 110
11.3.3 UK 113
11.3.4 REST OF EUROPE 117
11.4 ASIA PACIFIC 121
11.4.1 JAPAN 126
11.4.2 CHINA 130
11.4.3 INDIA 134
11.4.4 REST OF ASIA PACIFIC 139
11.5 REST OF THE WORLD (ROW) 142
12 COMPETITIVE LANDSCAPE 146
12.1 MARKET RANKING ANALYSIS 146
13 COMPANY PROFILES 147
(OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
13.1 BIOCEPT, INC. 147
13.2 QIAGEN N.V. 152
13.3 ROCHE DIAGNOSTICS 157
13.4 BIO-RAD LABORATORIES, INC. 160
13.5 MYRIAD GENETICS, INC 164
13.6 MENARINI-SILICON BIOSYSTEMS 167
13.7 TROVAGENE, INC. 170
13.8 GUARDANT HEALTH, INC. 174
13.9 MDXHEALTH SA 177
13.10 GENOMIC HEALTH, INC. 181
13.11 RAINDANCE TECHNOLOGIES, INC 184
13.12 THERMO FISHER SCIENTIFIC INC. 188
13.13 ILLUMINA, INC. 191
*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments, Key relationships might not be captured in case of unlisted companies.
14 APPENDIX 195
LIST OF TABLES
TABLE 1 CONFERENCES AND AWARENESS PROGRAMS ON LIQUID BIOPSY 38
TABLE 2 LIQUID BIOPSY PRODUCTS LAUNCHED IN RECENT YEARS 40
TABLE 3 LIQUID BIOPSY MARKET: FUNDING (2014 - 2017) 41
TABLE 4 COMPANIES SELLING/DEVELOPING LIQUID BIOPSY TESTS FOR ONCOLOGY,
IN THE US 47
TABLE 5 LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE, 2015–2022 (USD MILLION) 47
TABLE 6 LIQUID BIOPSY MARKET FOR ASSAY KITS, BY COUNTRY,
2015–2022 (USD MILLION) 48
TABLE 7 SPECIFICATIONS: NGS AND DDPCR FOR CANCER LIQUID BIOPSIES 50
TABLE 8 LIQUID BIOPSY MARKET FOR INSTRUMENTS, BY COUNTRY,
2015–2022 (USD MILLION) 50
TABLE 9 LIQUID BIOPSY MARKET FOR SERVICES, BY COUNTRY, 2015–2022 (USD MILLION) 51
TABLE 10 ADVANTAGES AND LIMITATIONS OF CTCS, CTDNA, AND EXOSOMES 53
TABLE 11 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER,
2015–2022 (USD MILLION) 53
TABLE 12 COMPANIES ACTIVE IN THE CTCS SEGMENT 54
TABLE 13 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY COUNTRY,
2015–2022 (USD MILLION) 55
TABLE 14 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY COUNTRY,
2015–2022 (USD MILLION) 56
TABLE 15 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY COUNTRY,
2015–2022 (USD MILLION) 57
TABLE 16 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY COUNTRY,
2015–2022 (USD MILLION) 59
TABLE 17 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY COUNTRY, 2015–2022 (USD MILLION) 60
TABLE 18 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2015–2022 (USD MILLION) 62
TABLE 19 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY COUNTRY/REGION, 2015–2022 (USD THOUSANDS) 63
TABLE 20 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 64
TABLE 21 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 65
TABLE 22 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 66
TABLE 23 LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 68
TABLE 24 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 69
TABLE 25 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE,
2015–2022 (USD MILLION) 70
TABLE 26 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 71
TABLE 27 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 73
TABLE 28 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 74
TABLE 29 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 75
TABLE 30 LIQUID BIOPSY MARKET FOR LIVER CANCER, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 76
TABLE 31 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 78
TABLE 32 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 79
TABLE 33 LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 81
TABLE 34 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 82
TABLE 35 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES,
BY COUNTRY/ REGION, 2015–2022 (USD MILLION) 83
TABLE 36 LIQUID BIOPSY MARKET FOR ACADEMIC AND RESEARCH CENTERS, BY COUNTRY/ REGION, 2015–2022 (USD MILLION) 84
TABLE 37 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY/REGION,
2015–2022 (USD MILLION) 85
TABLE 38 LIQUID BIOPSY MARKET, BY REGION, 2015–2022 (USD MILLION) 87
TABLE 39 ESTIMATED NEW CASES OF CANCER IN 2017, US 88
TABLE 40 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 90
TABLE 41 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 90
TABLE 42 NORTH AMERICA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET,
BY TYPE, 2015–2022 (USD MILLION) 90
TABLE 43 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 91
TABLE 44 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 91
TABLE 45 NORTH AMERICA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS,
BY CANCER TYPE, 2015–2022 (USD MILLION) 92
TABLE 46 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER,
2015–2022 (USD MILLION) 92
TABLE 47 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 94
TABLE 48 US: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 95
TABLE 49 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 95
TABLE 50 US: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 96
TABLE 51 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 96
TABLE 52 US: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 97
TABLE 53 OVERVIEW OF THE BREAST, CERVICAL, AND COLORECTAL CANCER SCREENING PROGRAMS ACROSS CANADA 98
TABLE 54 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 99
TABLE 55 CANADA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 99
TABLE 56 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 99
TABLE 57 CANADA: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 100
TABLE 58 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 100
TABLE 59 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 101
TABLE 60 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 103
TABLE 61 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 103
TABLE 62 EUROPE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 104
TABLE 63 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 104
TABLE 64 EUROPE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 105
TABLE 65 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 105
TABLE 66 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 106
TABLE 67 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 107
TABLE 68 GERMANY: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 107
TABLE 69 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 108
TABLE 70 GERMANY: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 108
TABLE 71 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 109
TABLE 72 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 109
TABLE 73 FRANCE: KEY MARKET INDICATORS 110
TABLE 74 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 110
TABLE 75 FRANCE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 111
TABLE 76 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 111
TABLE 77 FRANCE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 112
TABLE 78 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 112
TABLE 79 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 113
TABLE 80 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 114
TABLE 81 UK: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 115
TABLE 82 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 115
TABLE 83 UK: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 116
TABLE 84 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 116
TABLE 85 UK: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 117
TABLE 86 ROE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 118
TABLE 87 ROE: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 118
TABLE 88 ROE: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 119
TABLE 89 ROE: LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY CANCER TYPE, 2015–2022 (USD MILLION) 119
TABLE 90 ROE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 120
TABLE 91 ROE: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 120
TABLE 92 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 123
TABLE 93 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 123
TABLE 94 ASIA PACIFIC: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE, 2015–2022 (USD MILLION) 124
TABLE 95 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION,
2015–2022 (USD MILLION) 124
TABLE 96 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TYPE OF CANCER,
2015–2022 (USD MILLION) 125
TABLE 97 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 125
TABLE 98 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 126
TABLE 99 JAPAN: KEY MARKET INDICATORS 127
TABLE 100 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 127
TABLE 101 JAPAN: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 128
TABLE 102 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 128
TABLE 103 JAPAN: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015–2022 (USD MILLION) 129
TABLE 104 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 129
TABLE 105 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 130
TABLE 106 CHINA: KEY MARKET INDICATORS 131
TABLE 107 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 132
TABLE 108 CHINA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 132
TABLE 109 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 133
TABLE 110 CHINA: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015–2022 (USD MILLION) 133
TABLE 111 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 134
TABLE 112 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 134
TABLE 113 INDIA: KEY MARKET INDICATORS: 135
TABLE 114 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 136
TABLE 115 INDIA: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 136
TABLE 116 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 137
TABLE 117 INDIA: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015–2022 (USD MILLION) 137
TABLE 118 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 138
TABLE 119 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 138
TABLE 120 ROAPAC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 139
TABLE 121 ROAPAC: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 140
TABLE 122 ROAPAC: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 140
TABLE 123 ROAPAC: LIQUID BIOPSY MARKET, BY TYPE OF CANCER,
2015–2022 (USD MILLION) 141
TABLE 124 ROAPAC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 141
TABLE 125 ROAPAC: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 142
TABLE 126 ROW: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 143
TABLE 127 ROW: LIQUID BIOPSY CIRCULATING BIOMARKERS MARKET, BY TYPE,
2015–2022 (USD MILLION) 143
TABLE 128 ROW: LIQUID BIOPSY MARKET, BY APPLICATION, 2015–2022 (USD MILLION) 144
TABLE 129 ROW: LIQUID BIOPSY MARKET, BY TYPE OF CANCER, 2015–2022 (USD MILLION) 144
TABLE 130 ROW: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION,
2015–2022 (USD MILLION) 145
TABLE 131 ROW: LIQUID BIOPSY MARKET, BY END USER, 2015–2022 (USD MILLION) 145
TABLE 132 LIQUID BIOPSY MARKET, BY KEY PLAYER, 2016 146
TABLE 133 CHF TO USD CONVERSION RATES (2014-2016) 158
LIST OF FIGURES
FIGURE 1 LIQUID BIOPSY: MARKET SEGMENTATION 17
FIGURE 2 RESEARCH DESIGN 19
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 23
FIGURE 4 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 23
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 24
FIGURE 6 LIQUID BIOPSY MARKET, BY PRODUCT AND SERVICE, 2017 VS. 2022 27
FIGURE 7 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2017 VS. 2022 28
FIGURE 8 LIQUID BIOPSY MARKET, BY APPLICATION, 2017 VS. 2022 28
FIGURE 9 LIQUID BIOPSY MARKET, BY END USER, 2017 VS. 2022 29
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL LIQUID BIOPSY MARKET 30
FIGURE 11 INCREASING CANCER PREVALENCE—MAJOR GROWTH DRIVER FOR THE LIQUID BIOPSY MARKET 31
FIGURE 12 THERAPY SELECTION SEGMENT TO DOMINATE THE LIQUID BIOPSY MARKET
IN 2017 32
FIGURE 13 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2017 33
FIGURE 14 ASIA PACIFIC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 34
FIGURE 15 EMERGING MARKETS TO GROW AT HIGHER CAGRS FROM 2017 TO 2022 34
FIGURE 16 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 17 ESTIMATED NEW CANCER CASES AND ESTIMATED DEATHS IN US (2017) 36
FIGURE 18 CANCER PREVALENCE AND MORTALITY RATE, BY COUNTRY (2012) 37
FIGURE 19 PUBMED PUBLICATIONS—LIQUID BIOPSY 44
FIGURE 20 ESTIMATED NEW CANCER CASES AND DEATHS (2016) 69
FIGURE 21 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 89
FIGURE 22 US: CANCER STATISTICS 93
FIGURE 23 CANADA: CANCER STATISTICS 97
FIGURE 24 EUROPE: PROPORTION OF DEATHS DUE TO CANCER IN THE EU (2013) 101
FIGURE 25 EUROPE: DEATHS DUE TO CANCER IN THE POPULATION AGED 65
AND OVER (2013) 102
FIGURE 26 GERMANY: CANCER INCIDENCE AND PREVALENCE, 2010 VS. 2015 106
FIGURE 27 UK: ESTIMATED NUMBER OF PEOPLE LIVING WITH CANCER 113
FIGURE 28 ROE: INCIDENCE AND PREVALENCE OF CANCER, 2015 117
FIGURE 29 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT 122
FIGURE 30 JAPAN: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS. 2015 126
FIGURE 31 CHINA: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS 2015 131
FIGURE 32 INDIA: CANCER INCIDENCE AND PREVALENCE NUMBER, 2010 VS 2015 134
FIGURE 33 REST OF ASIA PACIFIC: NUMBER OF CANCER CASES, 2015 139
FIGURE 34 BIOCEPT, INC.: COMPANY SNAPSHOT (2016) 147
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2016) 153
FIGURE 36 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2016) 157
FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2016) 160
FIGURE 38 MYRIAD GENETICS, INC: COMPANY SNAPSHOT (2016) 164
FIGURE 39 MENARINI GROUP: COMPANY SNAPSHOT (2016) 167
FIGURE 40 TROVAGENE INC.: COMPANY SNAPSHOT (2016) 170
FIGURE 41 MDXHEALTH: COMPANY SNAPSHOT (2016) 177
FIGURE 42 GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2016) 181
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2016) 188
FIGURE 44 ILLUMINA INC.: COMPANY SNAPSHOT (2016) 191
プレスリリース
プレスリリース
当レポートのプレスリリースは発行されておりません。
リサーチカテゴリ一覧
スマートグリッド
生検装置の世界市場：2022年に至る製品別、用途別予測
お問合わせはこちらから
